Tilos Therapeutics Overview
- Founded
-
2016
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$773M
Tilos Therapeutics General Information
Description
Developer of antibody therapeutics designed to treat cancer, fibrosis and related disorders. The company's antibody therapeutics harnesses the power of the immune system to develop new therapies that target key immunological pathways with a primary focus on regulatory T cells and regulation of effector cells, enabling patients to start treatment more quickly, resulting in a better medical outcome.
Contact Information
Website
www.tilostherapeutics.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Acquirer
Primary Office
- 65 Hayden Avenue
- Lexington, MA 02421
- United States
Tilos Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Merger/Acquisition | 01-Jun-2019 | $773M | 00.00 | 00000 | Completed | Startup |
| 2. Seed Round | 21-Sep-2017 | 00.000 | 00.00 | 00.000 | Completed | Startup |
| 1. Seed Round | 30-Aug-2016 | $750K | $750K | 00.000 | Completed | Startup |
Tilos Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed | 0,000,000 | 00.000000 | 00 | 00 | 00 | 00 | 00 | 00.000 |
Tilos Therapeutics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Developer of antibody therapeutics designed to treat cancer, fibrosis and related disorders. The company's antibody ther
Biotechnology
Lexington, MA
00.00
0000
0000-00-00
000000&0
00.00
0000 0
psum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididu
0000000000000
San Diego, CA
000
As of 0000
00000
00000000
00000
0000 0
strud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis
0000000000000
Santa Monica, CA
000
As of 0000
00000
00.00
0000-00-00
000000&0
00000
Add Comparison
Tilos Therapeutics Competitors (120)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Fate Therapeutics | Formerly VC-backed | San Diego, CA | 000 | 00000 | 00000000 | 00000 |
| 0000 000000 | Formerly VC-backed | Santa Monica, CA | 000 | 00000 | 000000&0 | 00000 |
| 0000000 | Venture Capital-Backed | Cambridge, MA | 000 | 00000000000 | 000 | |
| 000000000 | Formerly VC-backed | Chicago, IL | 00 | 000000&0 | ||
| 000000 00000000000 | Venture Capital-Backed | Boston, MA | 00 | 00000 | 0000000000 0 | 00000 |
Tilos Therapeutics Patents
Tilos Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2022504839-A | Anti-lap antibody mutants and their use | Pending | 10-Oct-2018 | 000000000 | |
| US-20220017612-A1 | Anti-lap antibody variants and uses thereof | Pending | 10-Oct-2018 | 000000000 | |
| US-11130802-B2 | Anti-lap antibody variants | Active | 10-Oct-2018 | 000000000 | |
| EP-3863722-A2 | Anti-lap antibody variants and uses thereof | Pending | 10-Oct-2018 | 000000000 | |
| US-20200140530-A1 | Anti-lap antibody variants and uses thereof | Active | 10-Oct-2018 | C07K16/18 |
Tilos Therapeutics Former Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Boehringer Ingelheim Venture Fund | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Mass General Brigham Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| ShangPharma Innovation | Venture Capital | Minority | 000 0000 | 000000 0 |